Creating a database for patients with Thrombotic Thrombocytopenic Purpura

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to construct a comprehensive database for patients diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) by collecting detailed patient information through the Hitech case system and follow-up methods. The study will gather data on approximately 200 cases over a five-year period, focusing on patient demographics and clinical characteristics related to TTP. The data will be organized using Epidata software to facilitate analysis and improve understanding of the condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Subjects diagnosed with severe ADAMTS13 deficiency, defined as ADAMTS13 activity \<10%, documented in the patient's medical history or at screening.

Exclusion Criteria:

\- The investigator considers the subject unable or unwilling to cooperate with the study procedures.

Where it's running

• the first affiliated hospital of Soochow university
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Yue Han, Ph.D
• Email: hanyue@suda.edu.cn
• Phone: +86 18913091817

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with immune-mediated thrombotic thrombocytopenic purpura in Italy

  This study is tracking patients with immune-mediated thrombotic thrombocytopenic purpura in Italy to see how the disease affects them over time and what their treatment outcomes are.

  Recruiting Fondazione Luigi Villa · Milan, MI · NCT06376786

• Registry for patients with Thrombotic Thrombocytopenic Purpura in Turkey

  This study is collecting information from patients with Thrombotic Thrombocytopenic Purpura in Turkey to see how the disease is treated and how it affects their health over time.

  Recruiting Turkish Hematology Association · Ankara · NCT05950750

• CD20 antibody to prevent early EBV activation after a first allogeneic stem cell transplant

  Researchers are testing whether a CD20 monoclonal antibody can prevent EBV activation in people aged 14 to 70 after their first allogeneic stem cell transplant.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Hefei, Anhui and 9 other locations · NCT07929974

• BEBT-908 treatment for MEF2D-rearranged B-ALL that has come back or isn’t controlled

  This study tests BEBT-908 given IV to see if it can help people aged 14–75 with MEF2D-rearranged B-cell precursor ALL who have relapsed, are refractory, or still have measurable disease after treatment.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou · NCT07854652

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML

  We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07672262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.